Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770721 | 0.97 | CYP2D6 (0.45) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL12890875 | 0.92 | CYP2D6 (0.42) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL10254913 | 0.92 | CYP2D6 (0.42) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL12911789 | 0.89 | CYP2D6 (0.41) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL11947828 | 0.89 | CYP2D6 (0.41) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL24576857 | 0.87 | CYP2D6 (0.39) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL20071431 | 0.87 | CYP2D6 (0.39) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL22642328 | 0.87 | CYP2D6 (0.39) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL18390932 | 0.87 | CYP2D6 (0.44) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT | |
| SCHEMBL14768435 | 0.87 | CYP2D6 (0.39) | CYP2D6CHRNA7ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120252810-A1 | FATTY ACID NON-FLUSHING NIACIN DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213028-A1 | FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252810-A1 | FATTY ACID NON-FLUSHING NIACIN DERIVATIVES AND THEIR USES | NAMPT, FASN, FFAR2 | CYP2D6 603/4885CHRNA7 1020/4885ALDH1A1 1140/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | CYP2D6 3541/4885CHRNA7 3524/4885ALDH1A1 4099/4885 |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CYP2D6 2169/4885CHRNA7 3570/4885ALDH1A1 972/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2D6 2910/4885CHRNA7 4059/4885ALDH1A1 2230/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | CYP2D6 1066/4885CHRNA7 4746/4885ALDH1A1 634/4885 |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | ELOVL5, ELOVL3, ELOVL6 | CYP2D6 952/4885CHRNA7 4077/4885ALDH1A1 1295/4885 |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | SCD, SCD5, FASN | CYP2D6 2309/4885CHRNA7 3538/4885ALDH1A1 385/4885 |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | ELOVL1, FASN, FFAR2 | CYP2D6 1482/4885CHRNA7 4502/4885ALDH1A1 794/4885 |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | CYP2D6 942/4885CHRNA7 3790/4885ALDH1A1 544/4885 |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | CYP2D6 824/4885CHRNA7 780/4885ALDH1A1 606/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885CHRNA7 4420/4885ALDH1A1 2776/4885 |
| US-20110213028-A1 | FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES | FABP1, FFAR4, FABP3 | CYP2D6 297/4885CHRNA7 4217/4885ALDH1A1 1892/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CYP2D6 3897/4885CHRNA7 4633/4885ALDH1A1 1358/4885 |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | FASN, ELOVL3, FFAR2 | CYP2D6 1935/4885CHRNA7 4379/4885ALDH1A1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.